{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113883.3.7643.2.1006",
  "meta" : {
    "versionId" : "6",
    "lastUpdated" : "2019-01-08T01:00:08.000-05:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "Oncology Nursing Society Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2022-12-15"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2019-01-08"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.7643.2.1006",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.3.7643.2.1006"
    }
  ],
  "version" : "20190108",
  "name" : "CheckpointInhibitorsWithPotentialToCauseGrade3OrHigherFatigue",
  "title" : "Checkpoint Inhibitors with Potential to Cause Grade 3 or Higher Fatigue",
  "status" : "active",
  "experimental" : false,
  "date" : "2019-01-08T01:00:08-05:00",
  "publisher" : "Oncology Nursing Society Steward",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: This value set contains RxNORM concepts for various checkpoint inhibitor agents, regardless of dosage or administration route.),(Data Element Scope: Various drugs used in the treatment of cancer which may cause fatigue.),(Inclusion Criteria: atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab),(Exclusion Criteria: Brand name drugs and drug packs. Chemotherapy and biotherapy agents which may cause fatigue.)",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "concept" : [
          {
            "code" : "1657005",
            "display" : "40 ML ipilimumab 5 MG/ML Injection"
          },
          {
            "code" : "1657012",
            "display" : "10 ML ipilimumab 5 MG/ML Injection"
          },
          {
            "code" : "1657190",
            "display" : "4 ML nivolumab 10 MG/ML Injection"
          },
          {
            "code" : "1657195",
            "display" : "10 ML nivolumab 10 MG/ML Injection"
          },
          {
            "code" : "1657746",
            "display" : "pembrolizumab 50 MG Injection"
          },
          {
            "code" : "1657750",
            "display" : "4 ML pembrolizumab 25 MG/ML Injection"
          },
          {
            "code" : "1792780",
            "display" : "20 ML atezolizumab 60 MG/ML Injection"
          },
          {
            "code" : "1875542",
            "display" : "10 ML avelumab 20 MG/ML Injection"
          },
          {
            "code" : "1919507",
            "display" : "2.4 ML durvalumab 50 MG/ML Injection"
          },
          {
            "code" : "1919515",
            "display" : "10 ML durvalumab 50 MG/ML Injection"
          },
          {
            "code" : "1991412",
            "display" : "24 ML nivolumab 10 MG/ML Injection"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:d0bd8704-cf95-495d-af98-f4548ee78a48",
    "timestamp" : "2023-11-26T21:51:20-05:00",
    "total" : 11,
    "contains" : [
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11062023",
        "code" : "1657005",
        "display" : "40 ML ipilimumab 5 MG/ML Injection"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11062023",
        "code" : "1657012",
        "display" : "10 ML ipilimumab 5 MG/ML Injection"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11062023",
        "code" : "1657190",
        "display" : "4 ML nivolumab 10 MG/ML Injection"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11062023",
        "code" : "1657195",
        "display" : "10 ML nivolumab 10 MG/ML Injection"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11062023",
        "code" : "1657746",
        "display" : "pembrolizumab 50 MG Injection"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11062023",
        "code" : "1657750",
        "display" : "4 ML pembrolizumab 25 MG/ML Injection"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11062023",
        "code" : "1792780",
        "display" : "20 ML atezolizumab 60 MG/ML Injection"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11062023",
        "code" : "1875542",
        "display" : "10 ML avelumab 20 MG/ML Injection"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11062023",
        "code" : "1919507",
        "display" : "2.4 ML durvalumab 50 MG/ML Injection"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11062023",
        "code" : "1919515",
        "display" : "10 ML durvalumab 50 MG/ML Injection"
      },
      {
        "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
        "version" : "11062023",
        "code" : "1991412",
        "display" : "24 ML nivolumab 10 MG/ML Injection"
      }
    ]
  }
}
